Mean arterial pressure at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia

Tayyar, Ahmet; Krithinakis, Konstantinos; Wright, Alan; Wright, David; Nicolaides, Kypros H.

doi:10.1002/uog.15815

Cited by 36 publications

(25 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For all these predictors, the performance was better for early than for late PE, and was better when assessed later in pregnancy than at 11–13 weeks, i.e. closer to the development of PE.…”

Section: Combined Screening Strategiesmentioning

confidence: 96%

“…Combined screening has been the subject of approximately 400 PubMed articles up to April 2018. Multiple studies have shown that women who go on to develop PE have, on average, higher mean arterial pressure, higher concentrations of maternal serum soluble fms‐like tyrosine kinase‐1 (sFlt‐1) and alpha‐fetoprotein (AFP), and lower concentrations of pregnancy‐associated plasma protein‐A (PAPP‐A) and PlGF, along with higher resistance in the uterine arteries, compared with women who do not. For all these predictors, the performance was better for early than for late PE, and was better when assessed later in pregnancy than at 11–13 weeks, i.e.…”

Section: Combined Screening Strategiesmentioning

confidence: 99%

See 1 more Smart Citation

ISUOG Practice Guidelines: role of ultrasound in screening for and follow‐up of pre‐eclampsia

Sotiriadis

Hernández‐Andrade

Costa

et al. 2018

Ultrasound in Obstet & Gyne

140

115

View full text Add to dashboard Cite

RESUMEN Pautas de práctica de ISUOG: la función del ultrasonido en la detección y seguimiento de la preeclampsia Introducción La hipertensión en el embarazo afecta hasta el 10% de las mujeres embarazadas y la incidencia global combinada de la preeclampsia (PE) es de aproximadamente el 3%. Las diferencias significativas entre los países desarrollados y en desarrollo pueden atribuirse a diferencias reales o a diferencias derivadas de la adquisición de datos. La PE y sus complicaciones contribuyen en gran medida a la morbilidad y mortalidad materna y perinatal en todo el mundo. Dado que la atención oportuna y efectiva puede mejorar los resultados de la PE, el desarrollo de estrategias eficaces de predicción y prevención ha sido uno de los principales objetivos de la atención prenatal y de la investigación. La PE es una enfermedad multisistémica de origen multifactorial: está relacionada con placentación defectuosa, estrés oxidativo, autoinmunidad, activación de plaquetas y trombina, inflamación intravascular, disfunción endotelial, desequilibrio en la angiogénesis y mala adaptación cardíaca materna. La invasión defectuosa de la placenta está fuertemente asociada con la mayoría de los casos de PE temprana y grave. En contraste, la placentación defectuosa parece ser menos importante para el desarrollo de la PE que se manifiesta más tarde en el embarazo, por ejemplo después de las 34 semanas. En comparación con los embarazos afectados por la enfermedad de aparición temprana, en aquellos complicados con PE a término o cerca de este, la frecuencia de anomalías histológicas de las placentas es significativamente menor, y los factores maternos (p. ej. el síndrome metabólico o la hipertensión crónica) tienen una importancia relativamente mayor. También se observan diferencias entre la PE de aparición temprana y la de aparición tardía en los factores de riesgo, la capacidad de respuesta vascular materna, el rendimiento del cribado y la eficacia de la prevención. El conocimiento cada vez mayor sobre la fisiopatología de la PE se refleja en las estrategias de cribado actuales, que se basan en el historial, la demografía, los biomarcadores (como la presión arterial) y el Doppler de la arteria uterina. Actualmente hay más de 10 000 artículos de PubMed relacionados con la detección de la PE, lo que indica el gran interés en este tema. Menos de una quinta parte de estos se refieren a la detección temprana, lo que constituye un avance de la última década. El objetivo de estas Pautas es revisar la evidencia más reciente y, en lo posible, proporcionar recomendaciones basadas en la evidencia con respecto a la función del ultrasonido en el cribado y seguimiento de la PE. Las Pautas se centran en los aspectos técnicos y clínicos del cribado, sin incluir los aspectos económicos y políticos de la salud, como la conveniencia y la rentabilidad del cribado. Además, estas Pautas se elaboraron partiendo del supuesto de que se dispone de los recursos necesarios para la realización del cribado y el seguimiento (equipo, examinadores y conocimient...

show abstract

Section: Combined Screening Strategiesmentioning

confidence: 96%

Section: Combined Screening Strategiesmentioning

confidence: 99%

ISUOG Practice Guidelines: role of ultrasound in screening for and follow‐up of pre‐eclampsia

Sotiriadis

Hernández‐Andrade

Costa

et al. 2018

Ultrasound in Obstet & Gyne

140

115

View full text Add to dashboard Cite

show abstract

“…Mean arterial pressure (MAP), a biophysical marker is known to be a better predictor for screening preeclampsia [15] [16]. It represents average pressure in a patient's arteries during one cardiac cycle and is considered as a better indica-…”

Section: Introductionmentioning

confidence: 99%

Relationship between Mean Arterial Pressure, Uric Acid and Calcium with Xanthine Oxidase Activity and Fetal Outcome in Normotensive and Preeclampsia in a Nested Study

Gadde¹,

Doddaiah²,

Rangappa³

2018

OJOG

View full text Add to dashboard Cite

Preeclampsia is a pregnancy complication; early identification with increased risk is one of the key goals in obstetrics. In a nested case control study, serum uric acid and calcium measured in first and second trimesters of pregnancy were correlated with Xanthine oxidase (XO) activity, mean arterial pressure (MAP) and fetal birth weight. The mean ± SD of uric acid (2.01 ± 0.85, 4.8 ± 1.93), calcium (10.88 ± 1.97, 9.72 ± 2.04), MAP (84.32 ± 6.71, 78.40 ± 8.53) and XO activity (11.96 ± 1.91, 14.05 ± 3.09) of the study group (n=86) were observed in the first and second trimesters respectively. First trimester normotensive group (n=79) and preeclampsia cases (n = 7), showed a mean ± SD of uric acid (1.93 ± 0.80, 2.9 ± 0.88), Calcium (10.92 ± 1.9, 10.6 ± 1.72), MAP (84.19 ± 6.75, 85.71 ± 6.58) XO activity (11.82 ± 1.83, 13.57 ± 2.21). In the second trimester, normotensive group and preeclampsia cases showed a mean ± SD uric acid (4.6 ± 1.75, 7.3 ± 2.19), Calcium (9.4 ± 1.85, 12.9 ± 1.04), MAP (76.41 ± 5.41, 100.95 ± 2.52) and XO activity (13.37 ± 1.93, 21.70 ± 3.50). Statistical analysis revealed a non-significant positive correlation in first trimester between uric acid and MAP (r = +0.116, p = 0.288), negative correlations between uric acid and fetal birth weight (r = −0.118, 0.279) and between calcium and MAP (r = −0.288, p = 0.007). In the second trimester, significant positive correlations were observed between uric acid (r = +0.246, p = 0.022), calcium (r = +0.326, p = 0.007) with MAP along with a significant negative correlation between uric acid (r = −0.641, p = 0.000), calcium (r = −0.316, p = 0.003), Proteinuria (r = −0.514, p = 0.000) with fetal birth weight. The screening of first and second trimesters XO activity, uric acid, calcium and MAP during pregnancy is beneficial in identifying women likely to develop

show abstract

“…Second, many potential biomarkers have been extensively investigated and it has been established that, at present, useful biomarkers for the prediction of PE are: uterine artery pulsatility index (UtA‐PI), mean arterial pressure (MAP) and serum placental growth factor (PlGF) measured at 11–13 and 19–24 weeks' gestation; UtA‐PI, MAP, PlGF and serum soluble fms‐like tyrosine kinase‐1 (sFlt‐1) measured in the early third trimester; and MAP, PlGF and sFlt‐1 evaluated in the late third trimester. The methodology for obtaining appropriate measurements of biomarkers and auditing of results has also been established.…”

mentioning

confidence: 99%

“…Consequently, appropriate evaluation and application of biomarkers in screening requires prior standardization by expressing the measured values as multiples of the median (MoM). In pregnancies that develop PE, MoM values of MAP, UtA‐PI and sFlt‐1 tend to be higher and PlGF tends to be lower than in normal pregnancies; the effect size increases with increasing severity of the disease, quantified by the gestational age at delivery.…”

mentioning

confidence: 99%

Re: Prediction of pre‐eclampsia: review of reviews

Nicolaides

Wright

2019

Ultrasound in Obstet & Gyne

Self Cite

View full text Add to dashboard Cite

Mean arterial pressure at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia

Abstract: Objective To examine the distribution of mean arterial pressure (MAP) at 12, 22,

Cited by 36 publications

References 16 publications

ISUOG Practice Guidelines: role of ultrasound in screening for and follow‐up of pre‐eclampsia

ISUOG Practice Guidelines: role of ultrasound in screening for and follow‐up of pre‐eclampsia

Relationship between Mean Arterial Pressure, Uric Acid and Calcium with Xanthine Oxidase Activity and Fetal Outcome in Normotensive and Preeclampsia in a Nested Study

Re: Prediction of pre‐eclampsia: review of reviews

Contact Info

Product

Resources

About